Intellia Therapeutics (NTLA) Tops Q2 EPS by 4c, Revenues Beat

August 1, 2019 7:45 AM

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.56), $0.04 better than the analyst estimate of ($0.60). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found